| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CVSM.2010.07.006 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0195561610000938?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0195561610000938?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 20933143 |
| P50 | author | Lauren A Trepanier | Q87893730 |
| P2093 | author name string | Daniel S. Foy | |
| P2860 | cites work | Multiple oral dosing of ketoconazole increases dog exposure to ivermectin | Q80864606 |
| Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia | Q24563657 | ||
| Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Terbinafine: mode of action and properties of the squalene epoxidase inhibition | Q28284524 | ||
| Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia | Q28284944 | ||
| Posaconazole: an oral triazole with an extended spectrum of activity | Q28291282 | ||
| Cyclosporine and itraconazole interaction in heart and lung transplant recipients | Q28330585 | ||
| In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi | Q28343817 | ||
| Sodium status influences chronic amphotericin B nephrotoxicity in rats | Q28359697 | ||
| Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects | Q28367515 | ||
| Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts | Q28368930 | ||
| Terbinafine. An update of its use in superficial mycoses | Q28370491 | ||
| Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi | Q33188045 | ||
| Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care? | Q33608492 | ||
| Unusual lipid structures selectively reduce the toxicity of amphotericin B. | Q33641360 | ||
| Safety and efficacy of amphotericin B colloidal dispersion. An overview | Q33679648 | ||
| In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? | Q33692198 | ||
| Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). | Q33859215 | ||
| In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum | Q33979873 | ||
| A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections | Q33980885 | ||
| Echinocandins: the newest class of antifungals | Q34019188 | ||
| Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats | Q34265019 | ||
| Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. | Q34294886 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions | Q34458355 | ||
| Can we decrease amphotericin nephrotoxicity? | Q34503056 | ||
| Ketoconazole Hepatotoxicity in a Patient Treated for Environmental Illness and Systemic Candidiasis | Q34586413 | ||
| Update in antifungal therapy of dermatophytosis | Q34778510 | ||
| Voriconazole: a new triazole antifungal agent | Q35069136 | ||
| Adverse effects of ketoconazole in dogs--a retrospective study. | Q46545511 | ||
| Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae | Q46577790 | ||
| Treatment of blastomycosis with itraconazole in 112 dogs | Q48873837 | ||
| N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. | Q50530624 | ||
| Tissue Distribution of Amphotericin B Lipid Complex in Laboratory Animals | Q50799275 | ||
| Cryptococcal infection in cats: factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats. | Q50958320 | ||
| Upper-airway obstruction and prolonged recovery from anesthesia following intranasal clotrimazole administration. | Q51544043 | ||
| Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. | Q51634445 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance | Q56837291 | ||
| Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group | Q67716791 | ||
| Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole | Q67916894 | ||
| A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group | Q68094590 | ||
| Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole | Q68128738 | ||
| Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole | Q69823575 | ||
| Amphotericin B in liposomes: a novel therapy for histoplasmosis | Q70363742 | ||
| Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties | Q72052527 | ||
| Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity | Q72265660 | ||
| Endocrinological effects of single daily ketoconazole administration in male beagle dogs | Q72399820 | ||
| Interaction of itraconazole and digoxin | Q72958015 | ||
| Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole | Q73144789 | ||
| Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs | Q73203964 | ||
| The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats | Q73229872 | ||
| Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole | Q77577067 | ||
| Long-term outcome of therapy for 59 cats and 11 dogs with cryptococcosis | Q79339564 | ||
| Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole | Q79512224 | ||
| Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus | Q80416620 | ||
| Lipid formulations of amphotericin B: recent progress and future directions | Q40941280 | ||
| Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes | Q40994884 | ||
| Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections | Q41032451 | ||
| Role of azoles in antifungal therapy | Q41045041 | ||
| The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity | Q41644611 | ||
| Fluconazole-induced congenital anomalies in three infants | Q42553585 | ||
| Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q42683781 | ||
| Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis | Q42697516 | ||
| Intranasal infusion of clotrimazole for the treatment of nasal aspergillosis in two cats. | Q43242739 | ||
| Emerging targets for the development of novel antifungal therapeutics | Q43458604 | ||
| Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses. | Q43760403 | ||
| Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs | Q43823786 | ||
| In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin | Q44023532 | ||
| A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis | Q44166464 | ||
| Intranasal infusion of enilconazole for treatment of sinonasal aspergillosis in dogs. | Q44233942 | ||
| Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994-2007). | Q44392238 | ||
| Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding | Q44440251 | ||
| The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human | Q44447139 | ||
| Fungal rhinitis and sinusitis in three cats | Q44450548 | ||
| Comparative efficacies of oral ketoconazole and terbinafine for reducing Malassezia population sizes on the skin of Basset Hounds. | Q44468393 | ||
| Comparison of the clinical efficacy of oral terbinafine and ketoconazole combined with cephalexin in the treatment of Malassezia dermatitis in dogs--a pilot study | Q44469194 | ||
| Liver failure in a child receiving highly active antiretroviral therapy and voriconazole | Q44573512 | ||
| Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study | Q44832013 | ||
| Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid | Q44868355 | ||
| Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole | Q44973763 | ||
| Comparison of an antifungal agent with a mixture of antifungal, antibiotic and corticosteroid agents for the treatment of Malassezia species otitis in dogs | Q45075439 | ||
| Painful peripheral neuropathy associated with voriconazole use. | Q45218965 | ||
| Effect of ketoconazole on cyclosporine dose in healthy dogs. | Q45972240 | ||
| Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses. | Q46017312 | ||
| Influence of sodium intake on Amphotericin B-induced nephrotoxicity among extremely premature infants | Q46198306 | ||
| pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model | Q46397050 | ||
| Lipid formulations of amphotericin B: clinical efficacy and toxicities | Q46460941 | ||
| A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. | Q35179541 | ||
| The lipid formulations of amphotericin B. | Q35183734 | ||
| Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans | Q35572405 | ||
| Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys | Q35639881 | ||
| Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs | Q35825552 | ||
| Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults | Q35825919 | ||
| Histoplasmosis in dogs and cats | Q36326888 | ||
| Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats | Q36326893 | ||
| Micafungin: a new echinocandin | Q36436847 | ||
| Emerging echinocandins for treatment of invasive fungal infections | Q36458402 | ||
| Canine nasal aspergillosis | Q36482849 | ||
| Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men | Q36489989 | ||
| New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage | Q36597431 | ||
| The echinocandins | Q36742397 | ||
| Update on canine sinonasal aspergillosis | Q36908085 | ||
| Renal impairment and amphotericin B formulations in patients with invasive fungal infections | Q37103784 | ||
| Update on azole antifungals | Q37118861 | ||
| Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. | Q37119650 | ||
| Terbinafine: An oral and topical antifungal agent | Q37135324 | ||
| Clinicopathologic and diagnostic imaging characteristics of systemic aspergillosis in 30 dogs | Q37223834 | ||
| Coccidioidomycosis in dogs and cats: a review | Q37258080 | ||
| Invasive aspergillosis: diagnosis, prophylaxis and treatment | Q37285668 | ||
| Evidence-based veterinary dermatology: a systematic review of interventions for Malassezia dermatitis in dogs. | Q37371955 | ||
| Overview of antifungal agents | Q37449812 | ||
| Terbinafine: a pharmacological and clinical review | Q37623829 | ||
| Safety of triazole antifungal drugs in patients with cancer | Q37662650 | ||
| Administering amphotericin B--a practical approach | Q39134411 | ||
| Effect of salt supplementation on amphotericin B nephrotoxicity | Q39185944 | ||
| Itraconazole for the treatment of histoplasmosis in cats | Q39387576 | ||
| Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. | Q39558155 | ||
| Treatment of histoplasmosis and blastomycosis | Q39633435 | ||
| In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms | Q39743508 | ||
| How do the polyene macrolide antibiotics affect the cellular membrane properties? | Q39750989 | ||
| AmBisome targeting to fungal infections | Q40498735 | ||
| Liposomal amphotericin B, AmBisome | Q40698241 | ||
| Clinical use of liposomal and lipid-complexed amphotericin B. | Q40705427 | ||
| Oral azole drugs as systemic antifungal therapy | Q40796244 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1171-1188 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Veterinary Clinics of North America: Small Animal Practice | Q15765188 |
| P1476 | title | Antifungal treatment of small animal veterinary patients | |
| Antifungal Treatment of Small Animal Veterinary Patients | |||
| P478 | volume | 40 |
| Q44856929 | Alternate-day dosing of itraconazole in healthy adult cats |
| Q47284088 | Candidate prognostic indicators in cats with histoplasmosis treated with antifungal therapy |
| Q40090449 | Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs. |
| Q38131855 | Cryptococcosis as an emerging systemic mycosis in dogs |
| Q37454223 | Cytological, microbiological and therapeutic aspects of systemic infection in a dog caused by the fungus Phialosimplex caninus |
| Q36625752 | Disseminated Chrysosporium infection in a German shepherd dog. |
| Q91645785 | Inhibitors of Brassinosteroid Biosynthesis and Signal Transduction |
| Q93228151 | Long term survival of a dog with disseminated Aspergillus deflectus infection without definitive treatment |
| Q30585034 | Phaeohyphomycoses, emerging opportunistic diseases in animals |
| Q41001936 | Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs |
| Q58096339 | Therapy of Non-Dermatophytic Mycoses in Animals |
Search more.